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Background—Heart failure with preserved ejection fraction is a clinical syndrome that has been associated with changes in 
the extracellular matrix. The purpose of this study was to determine whether profibrotic biomarkers accurately reflect the 
presence and severity of disease and underlying pathophysiology and modify response to therapy in patients with heart 
failure with preserved ejection fraction.
Methods and Results—Four biomarkers, soluble form of ST2 (an interleukin-1 receptor family member), galectin-3, matrix 
metalloproteinase-2, and collagen III N-terminal propeptide were measured in the Prospective Comparison of ARNI 
With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) trial at baseline, 12 
and 36 weeks after randomization to valsartan or LCZ696. We examined the relationship between baseline biomarkers, 
demographic and echocardiographic characteristics, change in primary (change in N-terminal pro B-type natriuretic 
peptide) and secondary (change in left atrial volume) end points. The median (interquartile range) value for soluble form 
of ST2 (33 [24.6–48.1] ng/mL) and galectin 3 (17.8 [14.1–22.8] ng/mL) were higher, and for matrix metalloproteinase-2 
(188 [155.5–230.6] ng/mL) lower, than in previously published referent controls; collagen III N-terminal propeptide 
(5.6 [4.3–6.9] ng/mL) was similar to referent control values. All 4 biomarkers correlated with severity of disease as 
indicated by N-terminal pro B-type natriuretic peptide, E/E′, and left atrial volume. Baseline biomarkers did not modify 
the response to LCZ696 for lowering N-terminal pro B-type natriuretic peptide; however, left atrial volume reduction 
varied by baseline level of soluble form of ST2 and galectin 3; patients with values less than the observed median (<33 
ng/mL soluble form of ST2 and <17.8 ng/mL galectin 3) had reduction in left atrial volume, those above median did 
not. Although LCZ696 reduced N-terminal pro B-type natriuretic peptide, levels of the other 4 biomarkers were not 
affected over time.
Conclusions—In patients with heart failure with preserved ejection fraction, biomarkers that reflect collagen homeostasis 
correlated with the presence and severity of disease and underlying pathophysiology, and may modify the structural 
response to treatment.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00887588.   
(Circ Heart Fail. 2016;9:e002551. DOI: 10.1161/CIRCHEARTFAILURE.115.002551.)
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2  Zile et al  Biomarkers in HFpEF 
Several novel circulating biomarkers have been used to char-acterize the molecular and cellular changes that occur dur-
ing the development of myocardial disease.1–4 In heart failure 
(HF), these include biomarkers that reflect hemodynamic status 
(such as natriuretic peptides), inflammation (such as interleu-
kins), and collagen homeostasis (such as collagen peptides and 
interstitial proteases).2 The profiles of these biomarkers seem 
to differ significantly in patients with HF with a reduced ejec-
tion fraction (EF) versus HF with a preserved EF (HFpEF.5–7 
The nature and extent to which biomarkers change in HFpEF 
as a function of disease severity, degree of left ventricular (LV) 
structural and functional abnormalities and demographics and 
comorbid conditions have not been fully defined. In addition, 
whether baseline biomarkers can modify the response to treat-
ment in HFpEF has not been examined. One potential mecha-
nism hypothesized to play a pivotal role in the development 
of HFpEF is a change in collagen homeostasis that results in 
extracellular matrix fibrosis and the development of abnormal 
diastolic function.8–12 Several molecular and cellular signaling 
pathways that result in a profibrotic milieu have been identified 
in previous studies but have not been specifically examined in 
randomized clinical trials in HFpEF.2,6,7
See Clinical Perspective
Patients enrolled in the Prospective Comparison of 
ARNI With ARB on Management of Heart Failure with 
Preserved Ejection Fraction trial (PARAMOUNT) had the 
clinical syndrome of heart failure and evidence of increased 
LV filling pressures (symptoms and signs of volume over-
load and increased N-terminal pro B-type natriuretic peptide 
[NT-proBNP]).13 We hypothesized that if changes in extra-
cellular matrix fibrillar collagen content lead to abnormal 
diastolic function, these patients should have changes in 
biomarkers reflecting this. The purpose of this study was 
to examine a selected portfolio of postulated profibrotic 
biomarkers in a defined population of HFpEF, relate these 
biomarkers to demographic characteristics, changes in LV 
structure and function, severity of disease and response to 
treatment. Given the post hoc nature of this analysis and its 
modest sample size, this study was envisioned as hypothesis 
generating providing provocative evidence that would lead to 
additional, larger, and more definitive studies.
Methods
Study Design
PARAMOUNT was a randomized, double-blind, parallel group, ac-
tive control trial described in detail in previous publications.13 Briefly, 
men and women aged ≥40 years old with an LVEF ≥45% and a docu-
mented history of heart failure with associated signs or symptoms 
(dyspnea on exertion, orthopnea, paroxysmal dyspnea, and periph-
eral edema) were eligible. Patients were required to have NT-proBNP 
>400 pg/mL at screening, be on diuretic therapy, and have a systolic 
blood pressure <140 or ≤160 mm Hg, or less if on ≥3 blood pres-
sure drugs at randomization, have an estimated glomerular filtration 
rate (eGFR) of at least 30 mL/min per 1.73 m2 at screening, and a 
potassium concentration of no >5.2 mmol/L. Patients were excluded 
if they had previous LVEF <45% at any time, isolated right heart 
failure because of pulmonary disease, dyspnea because of noncardiac 
causes, such as pulmonary disease, anemia, or severe obesity, primary 
valvular or myocardial diseases, or coronary artery or cerebrovascu-
lar disease needing revascularization within 3 months of screening 
or likely to need revascularization during the trial. The number of 
patients enrolled with atrial fibrillation on ECG at screening was lim-
ited to roughly 25% of the total. The study protocol was submitted to 
individual sites’ institutional review boards or ethics committees and 
all enrolled patients provided written informed consent. A data safety 
monitoring committee oversaw the program and reviewed trial data 
for patient safety at regular intervals.
Biomarkers
Plasma and serum were obtained for biomarker determination at 
baseline, 12, and 36 weeks after randomization. The baseline mea-
surements were made at randomization after a placebo run-in phase. 
Measurements after randomization to valsartan or LCZ696 were 
made in 12 and 36 weeks. NT-proBNP and matrix metalloprotein-
ase-2 (MMP-2) were measured in plasma and collagen III N-terminal 
propeptide (PIIINP) was measured in serum at Quest Diagnostics 
(Valencia, CA) using the Elecsys proBNP immunoassay (Roche 
Diagnostics, Indianapolis, IN), the Quantikine MMP-2 immunoassay 
(R and D Systems, Minneapolis, MN), and the UniQ PIIINP radioim-
munoassay (Orion Diagnostics, Espoo, Finland). The soluble form 
of ST-2 (sST-2, an interleukin-1 receptor family member) was mea-
sured in serum at Critical Diagnostics (San Diego, CA) using their 
Presage immunoassay, and Galectin 3 (Gal-3) was measured in serum 
at Clinical Reference Laboratories (Lenexa, KS) using an enzyme-
linked immunosorbent assay (BG Medicine, Waltham, MA).
Echocardiographic Study
Baseline echocardiograms were analyzed in the cardiovascu-
lar imaging core laboratory at Brigham and Women’s Hospital, 
Boston, MA. All measurements were made in triplicate in ac-
cordance with the recommendations of the American Society of 
Echocardiography.14 LV volumes, mass, relative wall thickness, 
mitral flow velocities, tissue Doppler velocities, LAV, and LVEF 
were calculated according to the recommendations of the American 
Society of Echocardiography.14 Left atrial strain and LV global lon-
gitudinal strain were measured using vendor-independent 2-dimen-
sional speckle tracking software.15
Statistical Analysis
Baseline characteristics were summarized by quartiles of each bio-
marker using counts and percentages for binary variables and means 
and SDs for continuous variables, with the exception of NT-proBNP, 
which is summarized via median (interquartile range [IQR]) because 
of skewness. Tests for trend across quartiles were conducted via χ2 
trend tests, linear regression, and Cuzick nonparametric trend test, 
as appropriate. Biomarker data were presented as mean±SEM, geo-
metric mean, and median (IQR) at baseline. Baseline biomarker data 
were compared with data measured at 12 and 36 weeks after random-
ization presented as median (IQR) for the entire study group and then 
divided according to treatment group (valsartan versus LCZ696).
Baseline biomarker data were compared qualitatively with refer-
ent control values. Referent control values were presented for com-
parison as median (IQR). Median (IQR) referent control data for 
PIIINP and MMP-2 were taken from a previously published study in 
which 241 subjects of age, sex, and race distribution similar to this 
study population were examined.5 However, these well-characterized 
subjects had no clinical, serological, or cardiac structural/functional 
abnormalities as evidenced by a normal echocardiography and 6-min-
ute hall walk distance. Median (IQR) referent control data for Gal-3 
were taken from a previously published study in which 1092 sub-
jects of age, sex, and race distribution similar to this study popula-
tion were examined.16 Median (IQR) referent control data for sST-2 
were aggregated from 3 previously published study (including the 
Framingham study) in which subjects of age, sex, and race distri-
bution similar to this study population were examined.17–20 Although 
small differences between men and women have been seen in the bio-
markers described above, because the populations of both this study 
and the referent control populations are roughly 50% female, the ref-
erent control values listed in Table 1 represent the total population 
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3  Zile et al  Biomarkers in HFpEF 
examined. In addition, biomarker data from this study of patients with 
HFpEF were compared with previously published groups of patients 
with HFpEF.5,21–24 Finally, Gal-3 and sST-2 data in this study were 
compared with Food and Drug Administration approved partition val-
ues for risk stratification; these partition values were not specifically 
designed for risk stratification in HFpEF but were targeted to overall 
risk in generalized populations.
Correlations between biomarkers and demographic and echocar-
diographic data were performed using Spearman correlation. Values 
for sST-2, Gal-3, and NT-proBNP were log transformed because they 
were noticeably right skewed. In a multivariable regression model 
that included age, sex, New York Heart Association class, history of 
atrial fibrillation, diastolic blood pressure, eGFR, log NT-pro BNP, 
LV transmitral early diastolic filling velocity/LV early diastolic myo-
cardial velocity (E/E′), and LA volume, we examined which factors 
were independently associated with baseline levels of biomarkers. 
Variables included were on the basis of low numbers of missing 
values and clinical knowledge. To examine the interaction between 
treatment with LCZ696 and baseline biomarker levels on levels of 
NT-proBNP at 12 weeks and LA volume at 36 weeks, we used a 
regression model that included the effect of LCZ696, an interaction 
term between treatment and baseline biomarker values and stratifica-
tion variables of region and previous angiotensin-converting-enzyme 
inhibitor or ARB use as well as baseline NT-proBNP and LA volume, 
respectively. Where an interaction was found this was explored fur-
ther by dividing the cohort into values above and below the observed 
median value of the biomarker and stratified models of the effect 
of treatment on NT-proBNP and LA volume examined. All statisti-
cal analyses were performed using STATA version 12 (Stata Corp, 
College Station, TX). For interaction tests a P<0.1 was considered 
suggestive of an interaction, and for all other test a P<0.05 was con-
sidered statistically significant.
Results
Demographic and Echocardiographic Data
Data from the 301 randomized patients were included in this 
study, 149 randomized to LCZ696 and 152 to valsartan. The 
demographic and echocardiographic data were typical of a 
stable outpatient HFpEF population29,30; elderly, female, and 
NYHA class II dominant, receiving multidrug treatment, 
expected comorbidities, and evidence of abnormal diastolic 
function with increased NT-proBNP, E/E′, and LA volume. 
Baseline data are presented for each individual biomarker 
examined by quartiles (Tables I–IV in the Data Supplement).
Baseline Biomarker Data
In these patients with HFpEF, the baseline median values for 
Gal-3 and sST-2, summarized in Table 1, were ≈50% higher 
than the median values from previously published referent 
control subjects.16–24 In these patients with HFpEF, the median 
values for MMP-2 were ≈50% lower and PIIINP were similar 
to previously published referent control subjects.5,31
There were significant correlations between baseline bio-
markers and demographic and echocardiographic variables 
(Table 2). Gal-3, sST-2, and PIIINP increased and MMP-2 
decreased in association with an increase in NT-proBNP, and 
decreased eGFR (Figure 1A). sST-2 increased and MMP-2 
decreased in association with an increase in E/E′ and LA vol-
ume (Figure 1B). There was also a direct relationship between 
sST-2 and Gal-3 (r=0.24, P<0.001; Figure 1C).
Table 1. Biomarker Data
PARAMOUNT-HF HFpEF Patients Referent Controls
Mean (SD) Geo Mean Median (IQR) Median*
sST2, ng/mL 39.6 (24.7) 34.7 33.0 (24.6–48.1) 20 (17–26)
Galectin-3, ng/mL 19.0 (6.9) 17.9 17.8 (14.1–22.8) 12 (9–15)
MMP-2, ng/mL 198 (73) 184 188 (156–231) 335 (323–443)
PIIINP, ng/mL 6.1 (3.5) 5.5 5.6 (4.3–6.9) 6.5 (6.1–8.2)
HFpEF indicates heart failure with preserved ejection fraction; IQR, interquartile range; 
MMPs, matrix metaloproteinases; PARAMOUNT, Prospective Comparison of ARNI With ARB on 
Management of Heart Failure with Preserved Ejection Fraction; PIIINP, collagen III N-terminal 
propeptide; and sST2, soluble form of ST2 (an Interleukin-1 receptor family member).
*Referent control median (IQR) values taken from the studies by Zile et al,5 Motiwala et al,25 
Wang et al,26 Bhardwaj et al,27 and Shah et al.28
Table 2. Correlations Between Biomarker and Demographic/Echocardiographic Data
ST2 Galectin MMP2 PIIINP
R P R P R P R P
NT-proBNP 0.19 0.002 0.17 0.004 0.31 <0.001 0.25 <0.001
eGFR −0.16 0.005 −0.50 <0.001 −0.19 0.002 −0.14 0.07
SBP −0.03 0.64 0.01 0.94 0.01 0.92 −0.04 0.60
E′ 0.07 0.31 −0.04 0.51 0.07 0.31 0.07 0.38
E/A 0.12 0.11 −0.04 0.57 0.24 0.003 −0.02 0.84
E/E′ 0.11 0.09 0.09 0.18 0.17 0.01 −0.03 0.70
LA volume 0.25 <0.001 −0.01 0.87 0.14 0.03 −0.04 0.65
A indicates atrial contraction induced diastolic filling velocity wave; E, early diastolic filling velocity; E′, early diastolic 
myocardial velocity; eGFR, estimated glomerular filtration rate; LA, left atrium; MMPs, matrix metaloproteinases, NT-proBNP, 
N-terminal pro-B-type natriuretic peptide; PIIINP, collagen III N-terminal propeptide; SBP, systolic blood pressure; and sST-2, 
soluble form of ST2 (an interleukin-1 receptor family member).
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4  Zile et al  Biomarkers in HFpEF 
In a multivariable model after adjusting for age, sex, NYHA 
class, history of atrial fibrillation, diastolic blood pressure, 
eGFR, log NT-proBNP, E/E′, and LA volume, only female 
sex (coefficient, −0.27 [95% CI, −0.40 to −0.14]; P<0.001), 
NYHA class (coefficient, 0.24 [0.09 to 0.39]; P=0.002), and 
LA volume (coefficient, 0.003 [0.0004 to 0.005]; P=0.02) 
were statistically significantly associated with higher sST2. 
Only female sex (coefficient, 0.168 [0.004–0.332]; P=0.04) 
and log NT-proBNP (coefficient, 0.10 [0.01–0.19]; P=0.03) 
were associated with baseline PIIINP. Lower diastolic blood 
pressure was associated with higher MMP-2 levels at baseline 
(coefficient, −0.014 [−0.023 to −0.006]; P=0.001), whereas 
lower eGFR was associated with higher Gal-3 (coefficient, 
−0.008 [−0.011 to −0.006]; P<0.001).
Relationship Between Biomarkers and LCZ696 
Treatment
The relationship between biomarkers and the effects of 
LCZ696 on the primary study end point (change in NT-
proBNP after 12 weeks of treatment) and the secondary 
study end point (change LA volume from baseline after 36 
weeks of treatment) were examined. There were no treatment 
interactions between LCZ696 and changes in NT-proBNP at 
12 weeks (primary end point) for any of the 4 biomarkers: 
MMP-2 (interaction P=0.40), PIIINP (interaction P=0.14), 
Gal-3 (interaction P=0.32), or sST2 (interaction P=0.63). 
In addition, there were no treatment interactions between 
LCZ696 and changes in NT-proBNP at 36 weeks for any of 
the 4 biomarkers: MMP-2 (interaction P=0.09), PIIINP (inter-
action P=0.5), Gal-3 (interaction P=0.2), or sST2 (interac-
tion P=0.99). However, there was an interaction between the 
response to treatment with LCZ696 compared with valsartan 
on change in LA volume at 36 weeks and baseline values of 
sST-2 (interaction P=0.07) and Gal-3 (interaction P=0.04). 
There was no interaction with PIIINP levels (interaction 
P=0.79) or MMP2 (interaction P=0.61).
We further explored the interaction with sST-2 and Gal-3 
by dividing patients into 2 groups, for those above and below 
the observed baseline median value of sST-2 (≥33.0 versus 
<33.0 ng/mL) or Gal-3 (≥17.8 versus <17.8 ng/mL). The 
effect on change in LA volume from baseline differed between 
LCZ696 and valsartan (Figure 2). In patients with a baseline 
value of sST-2 above the median, 36 weeks of treatment with 
LCZ696 did not result in a significant change in LA volume 
from baseline compared with valsartan (difference, −1.5; 95% 
CI, −7.8 to 4.8; P=0.6). Similarly in patients with a baseline 
value of Gal-3 above the median, treatment with LCZ696 did 
not result in a significant change in LA volume from base-
line compared with valsartan (difference, −1.8, 95% CI, −7.6 
to 4.0; P=0.5). In patients with a baseline value of sST-2 or 
Gal-3 below the median, 36 weeks of treatment with LCZ696 
resulted in a statistically significantly larger change from 
baseline in LA volume compared with valsartan (in those with 
sST-2 values below median, the difference in treatment effect 
between LCZ696 versus valsartan was −9.9; 95% CI, −15.1 to 
−4.8; P<0.0001, in those with Gal-3 values below the median 
treatment effect between LCZ696 versus valsartan was median 
difference −10.3; 95% CI, −15.6 to −5.0; P<0.0001).
For both patients with an NT-proBNP less than the median 
(difference, −4.1; 95% CI, −9.0 to 0.7; P=0.09) and patients 
with an NT-proBNP greater than the median (difference, −6.0; 
95% CI, −12.0 to 0.1; P=0.053), treatment with LCZ696 
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Figure 1. A, Relationship between ln(sST-2) and ln(NT-proBNP) in 
patients with heart failure with a preserved ejection fraction; Spear-
man correlation r=0.19, P=0.002. B, Relationship between ln(sST2) 
and left atrial volume (LAV) in patients with heart failure with a pre-
served ejection fraction; correlation r=0.25, P=0.002. C, Relation-
ship between ln(sST2) and ln(Gal-3) in patients with heart failure 
with a preserved ejection fraction; correlation r=0.23, P<0.0001. ; 
Gal-3 indicates galectin 3; NT-proBNP, N-terminal pro B-type natri-
uretic peptide; and sST-2, soluble suppressor of tumorigenicity-2.
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5  Zile et al  Biomarkers in HFpEF 
resulted in a numerically greater reduction in LA volume from 
baseline compared with valsartan. A formal test of the interac-
tion between randomized treatment and baseline NT-proBNP 
was not statistically significant (P for interaction=0.12). For 
patients with an eGFR less than the median (difference, −2.8; 
95% CI, −7.7 to 2.1; P=0.26) and patients with an eGFR 
greater than the median (difference, −8.8; 95% CI, −15.0 to 
−2.6; P=0.006), treatment with LCZ696 resulted in a numeri-
cally greater reduction in LA volume from baseline compared 
with valsartan. This change was statistically significant for 
the group with an eGFR greater than the median. However, 
a formal test of interaction between randomized treatment 
and baseline eGFR was not statistically significant (P for 
interaction=0.58).
Interactions between LCZ696 and all other echocardio-
graphic measurements of cardiac structure and function for 
the 4 biomarkers examined in this study were not performed 
because they were not listed as a priori end points and because 
our previous published studies showed that LCZ696 did not 
result in a change in any of these other echocardiographic 
parameters.13
There were no significant differences in any of the 4 bio-
marker values (sST-2, Gal-3, MMP-2, or PIIINP) between 
patients treated with valsartan versus LCZ696 at baseline or 
after 12 or 36 weeks of treatment (Table 3). This was true 
for the patient group as a whole and for subgroups with base-
line sST-2 and Gal-3 above and below the observed median 
values. Comparing baseline biomarker values to after treat-
ment values, MMP-2 increased significantly in both valsar-
tan- and LCZ696-treated patients at week 36 versus baseline 
(P<0.001); there were no significant changes in the other 3 
biomarkers comparing baseline with after treatment values.
History of atrial fibrillation was not associated with 
change in LA volume at 36 weeks P=0.12 and there was no 
interaction between randomized treatment and history of atrial 
fibrillation on change in LA volume P=0.44. In addition, for 
subjects with AF on ECG at baseline, the respective P values 
were also nonsignificant at 0.39 and 0.52.
Discussion
Data from this study support several novel and hypothesis 
generating findings. First, we found that patients with HFpEF 
had values of circulating biomarkers that may reflect a profi-
brotic state. Gal-3 and sST-2 were increased and MMP-2 was 
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Figure 2. Change from baseline in left atrial volume (LAV) pro-
duced by treatment with LCZ696 vs valsartan in those with a 
baseline value of soluble form of ST2 (sST-2) and galectin 3 (Gal-
3) above and below the median. When patients were divided into 
2 groups, above and below the baseline median value of sST-2 
or Gal-3, the effect on change in LA volume produced LCZ696 
vs valsartan differed; in patients with a baseline value of sST-2 or 
Gal-3 above the median, treatment with LCZ696 did not result 
in a significant change in LA volume; in patients with a baseline 
value of sST-2 or Gal-3 below the median, treatment with LCZ696 
resulted in a decrease in LA volume after 36 weeks of treatment 
compared with baseline.
Table 3. Serial Measurements of Plasma Biomarkers
sST2 Galectin-3 MMP-2 PIIINP
Baseline
  Sample Size 296 294 247 178
   All 33.0 (24.6–48.1) 17.8 (14.1–22.8) 188 (156–231) 5.6 (4.3–6.9)
   Valsartan 33.8 (25.2–48.1) 16.9 (14.0–22.4) 188 (156–244) 5.6 (4.3–6.8)
   LCZ696 32.2 (24.3–47.8) 18.9 (14.4–23.3) 187 (150–225) 5.5 (4.4–7.2)
12 wk
  Sample Size 262 250 244
   All 30.7 (23.4–44.7) 17.0 (13.9–22.1) 191 (155–234)
   Valsartan 31.0 (23.9–44.4) 17.1 (13.9–21.2) 194 (150–243)
   LCZ696 29.8 (23.3–45.8) 16.9 (14.2–22.2) 189 (158–222)
36 wk
  Sample Size 211 214 241 182
   All 33.4 (23.5–48.4) 16.8 (13.8–21.9) 253 (208–318) 5.3 (4.2–7.1)
   Valsartan 35.2 (23.6–45.1) 16.8 (13.8–21.2) 261 (212–334) 5.4 (4.1–7.0)
   LCZ696 31.4 (23.5–50.4) 17.0 (13.8–22.2) 248 (206–303) 5.3 (4.2–7.2)
All data are median (interquartile range) and in units of ng/mL. MMPs indicates matrix 
metaloproteinases; PIIINP, collagen III N-terminal propeptide; and sST-2, soluble form of ST2 
(an interleukin-1 receptor family member).
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decreased. Gal-3 and sST-2 have been shown to increase col-
lagen synthesis in cardiac fibroblasts and MMP-2 has been 
shown to cause collagen degradation2 (Figure 3). In aggregate, 
the directional changes in these biomarkers might be expected 
to be associated with an increase in myocardial collagen con-
tent. This study adds important, novel, clinically relevant data 
in a group of patients in which there is a large gap in knowl-
edge. In particular, the panel of specific biomarkers used in 
this study has not been examined together in previous clinical 
studies or randomized clinic trials of patients with HFpEF. In 
addition, PARAMOUNT represents the only phase II random-
ized clinic trial of patients with HFpEF in which the prespeci-
fied primary end points have been positively improved by the 
therapy being tested. This provided a unique opportunity to 
examine the purposes proposed and test the hypotheses stated 
in this study.
The differences between biomarkers in the current HFpEF 
patients and referent controls are concordant with trends found 
in the limited number of other studies that included patients 
with HFpEF. For example, in studies including patients with 
HFpEF, sST-2 median values ranged from ≈25 to 30 ng/
mL2,29–31 and Gal-3 median values ranged from ≈12 to 14 ng/
mL.2,21,22,31 Variations in inclusion/exclusion criteria creating 
differences in population characteristics, comorbidity distri-
bution, and severity of HF are likely responsible for small dif-
ferences between studies.
For both sST-2 and Gal-3, there are Food and Drug 
Administration approved partition values that can be used in 
risk assessment analyses to predict morbid and mortal out-
comes. When sST-2 is >35 ng/mL or Gal-3 is >17.8 ng/mL, 
there is an increase in risk. It should be noted; however, that 
both of these partition values were established from studies 
such as HF-ACTION and others in which patients with HFrEF 
were exclusively or dominantly the focus of study. It is fortu-
itous that the median values for these 2 biomarkers in this study 
are identical to or close to the Food and Drug Administration 
approved partition values. Therefore, these data lend credence 
to the important biomarker observations made in this study of 
patients with HFpEF in PARAMOUNT.
Second, we found that biomarker levels correlated with 
indices of disease severity. The presence of more severe 
HFpEF is generally indicated by higher levels of NT-proBNP, 
diastolic function (such as E/E′ and LAV) and decreased renal 
function.2,5,32–35 In this study, there was a direct relationship 
between sST-2 and each of these indices of disease severity; 
there was an inverse relationship with MMP-2. Thus, although 
each of the patients enrolled in PARAMOUNT had the clinical 
syndrome of HFpEF, those with the more severe disease had 
a biomarker pattern associated with a more profibrotic milieu. 
Although these interactions described in this study may have 
been expected, they have never been previously examined 
in a substantially sized study of patients with HFpEF. The 
interactions defined help to clarify signaling pathways that 
contribute to fibrosis-induced (and probably inflammation 
induced) abnormalities in structure and function in patients 
with HFpEF.
Third, the baseline pretreatment values of sST-2 and 
Gal-3 may have modified the response to LCZ696, specifi-
cally reduction in LA volume but not in NT-proBNP. Patients 
who had levels of sST-2 and Gal-3 below the observed median 
value showed a greater LA volume response to LCZ696 than 
those with sST-2 and Gal-3 above the median. These data are 
clearly not conclusive; however, they do allow the genera-
tion of important new hypotheses, particularly concerning the 
mechanisms underlying HFpEF and the effects of LCZ696 on 
these mechanisms. It is possible that patients with less severe 
myocardial fibrosis may be more responsive to treatment, 
particularly during a short period of treatment. Changes in 
LV structural remodeling may not be detectable until treat-
ment has been continued for at least 12 months. Confirmation 
of these findings in a larger patient cohort and extension of 
treatment duration will clearly be needed in future studies 
to make more definitive conclusions. These kind of analyses 
are planned for Prospective Comparison of ARNI With ARB 
Global Outcomes in Heart Failure With Preserved Ejection 
Fraction (PARAGON-HF).
There are several possible factors that contribute to the fact 
that baseline biomarkers modified the response to LCZ696 on 
LAV but not to NT-proBNP. For example, changes in natri-
uretic peptides and changes in left atrial structure/function may 
reflect different but interdependent aspects of the pathophysi-
ological mechanisms that underlie HFpEF. As presented in a 
previously published figure, LV diastolic filling pressures can 
be changed rapidly as a result of intravascular volume shifts and 
a change in operative compliance.2
 This hemodynamic change 
may be best reflected by changes in natriuretic peptides. LV 
diastolic filling pressures can also be changed more slowly by 
progressive fibrosis and a change in overall chamber compli-
ance.2 This structural change may be best reflected by changes 
in LAV. LCZ696 is likely to act on both of these mechanisms. 
Its direct diuretic, unloading, hemodynamic effect would be 
Mast cell
Galectin 3
Fibroblast
Myofibroblast
Profibrotic
Signaling
sST2L
IL-33
ST2
sST-2
MMP-2
HFpEF
Cell
membrane
Gal-3
Figure 3. Schematic representation of mechanisms suggested 
by changes in circulating biomarkers. Increased galectin 3 (gal-
3) secreted by mast cells may contribute to transdifferentiation 
of fibroblasts to myofibroblasts. Increased soluble form of ST2 
(sST-2) may contribute to ST-2 profibrotic signaling. Decreased 
matrix metalloproteinase-2 (MMP-2) may contribute to less col-
lagen degradation. In aggregate, these changes may contribute 
to increased myocardial extracellular matrix (ECM) collagen and 
fibrosis and may be reflected by the changes measured in circu-
lating biomarkers. HFpEF indicates heart failure with preserved 
ejection fraction; and IL, interleukin.
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expected to rapidly reduce filling volume, operative compli-
ance, and NT-proBNP and to do so without needed to also 
affect structural changes in myocardial extracellular matrix 
collagen or LAV. Therefore, the extent of fibrosis (as reflected 
by sST-2 or Gal-3) should not modify the effects of LCZ696 
on changes in NT-proBNP. By contrast, the effects of LCZ696 
on the regression of fibrosis would be expected to occur over 
longer time periods. Therefore, patients with less fibrosis (as 
reflected by lower values of sST-2 or Gal-3) may respond more 
quickly with a decrease in overall chamber compliance and a 
resultant decrease in LAV because there was simply less fibro-
sis to regress. Patients with more fibrosis may take longer than 
6 to 9 months to respond to LCZ696; however, this finding 
does not necessarily signal the absence of a response. There 
are few studies that document the time course of regression 
of fibrosis in pathophysiological processes that undergo treat-
ments that effectively correct the pathophysiological abnor-
malities. However, perhaps the best example is the effects of 
aortic valve replacement in patients with aortic valve steno-
sis. In these studies, the complete reversal of LV fibrosis was 
time dependent and progressive during a 2- to 4-year period 
after aortic valve replacement.36 Thus, the interplay between 
changes in hemodynamic and structural factors (and other fac-
tors) may contribute to the findings presented in this study.
Fourth, during the 36-week course of this study, sST-2, 
Gal-3, MMP-2, or PIIINP did not change in either the val-
sartan- or LCZ696-treated groups. The significance of this 
finding is not entirely clear. The same possible factors listed 
above may be applicable such as the length of the treatment 
period may be too short to see significant changes in these 
biomarkers. Conversely, it is possible that this particular set 
of biomarkers may have greater use as diagnostic, prognostic, 
and severity of illness indices rather than indices reflecting 
response to therapy.
Biomarkers Reflecting a Profibrotic State
Fibrillar collagen content can be altered by changes in the 
balance in the following processes: collagen synthesis, post-
synthetic processing, and degradation. Biomarkers reflect-
ing changes in these processes or their determinants were 
examined in PARAMOUNT.2,5–7 For example, Gal-3, a 
β-galactoside–binding lectin, secreted by macrophages, may 
act to increase fibroblast proliferation, activity, transformation 
into myofibroblast, and increase collagen synthesis.25–28,37–43 
Likewise, soluble ST2, by acting as a decoy, prevents bind-
ing of IL-33 to membrane-bound ST2 and results in increased 
collagen synthesis (Figure 3). Therefore, both Gal-3 and sST2 
induced increase in collagen synthesis would be expected to be 
reflected in an increase in levels of collagen propeptides, such 
as PIIINP (procollagen III N-terminal propeptide). However, 
in the presence of what seem to be profibrotic stimuli, we did 
not see changes in PIIINP. It is likely that the most important 
changes in myocardial collagen homeostasis involve a change 
in collagen I rather than collagen III, thus limiting the sensitiv-
ity of PIIINP versus measurements of collagen I propeptides. 
In addition to changes in synthesis, changes in degradation 
may affect collagen content. Insoluble collagen fibril degra-
dation is caused by proteases such as MMPs, of which there 
are >29 known members.5–11 Only MMP-2 was measured in 
PARAMOUNT; lower values seen in patients with HFpEF 
suggests decreased degradation rates; however, measurement 
of this single MMP particularly without measurement of tis-
sue inhibitors of MMPs does not fully characterize the stoi-
chiometric balance of this enzyme system.
Study Limitations
We readily acknowledge that comparing biomarker data from 
this study with nonsimultaneous, historic, previously pub-
lished referent controls imposes clear limitations. Although a 
referent control group was not included in the design of the 
PARAMOUNT study, the previously published referent con-
trol subjects used for comparison were taken from subjects 
with an age, sex, and race distribution similar to this study 
population but with no evidence of active cardiovascular dis-
ease. In addition, the methodologies used in this study to mea-
sure biomarkers were either identical to or equivalent to the 
methods used in previously published studies. The small dif-
ferences in methodologies are not likely to impose significant 
differences between study analyses.
Measurements of circulating biomarkers are not direct 
measurements of myocardial collagen homeostasis. Our anal-
ysis assumes that biomarkers are representatively excreted in 
a manner measureable in the circulation and that their pre-
dominant source is the myocardium. PARAMOUNT was 
designed with exclusion criteria that limited comorbid condi-
tions that would produce nonmyocardial sources of circulat-
ing biomarkers that reflect changes in collagen homeostasis, 
such as severe renal, pulmonary, or hepatic fibrosis.
Conclusions
In patients with HFpEF, biomarkers that reflect collagen 
homeostasis correlated with the presence and severity of dis-
ease and underlying pathophysiology, and may modify the 
structural response to treatment.
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CLINICAL PERSPECTIvE
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome that has been associated with changes in the 
extracellular matrix. The purpose of this analysis was to examine a selected portfolio of postulated profibrotic biomarkers in 
a defined population of HFpEF, relate these biomarkers to demographic characteristics, changes in left ventricular structure 
and function, severity of disease, and response to treatment. Data from this analysis support several novel and hypothesis-
generating findings. First, patients with HFpEF have circulating biomarkers that reflect a profibrotic state. Galectin 3 and 
soluble form of ST2 were increased and matrix metalloproteinase-2 was decreased. In aggregate, these directional changes 
in these biomarkers might be expected to be associated with an increase in myocardial collagen content. Second, biomarker 
levels correlate with indices of disease severity. Although each of the patients enrolled in the Prospective Comparison of 
ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction trial (PARAMOUNT) had the clinical 
syndrome of HFpEF, those with the more severe disease had a biomarker pattern associated with a more profibrotic milieu. 
Third, the baseline pretreatment values of soluble form of ST2 and galectin 3 may have modified the response to LCZ696, 
specifically reduction in left atrial volume. Patients who had levels of soluble form of ST2 and galectin 3 below the observed 
median value showed a greater left atrial volume response to LCZ696 than those with soluble form of ST2 and galectin 3 
above the median. In patients with HFpEF, biomarkers that reflect collagen homeostasis correlated with the presence and 
severity of disease and underlying pathophysiology, and may modify the structural response to treatment.
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Supplemental TABLE 1. Baseline Characteristics According to GALECTIN-3 by Quartiles 
 Q1, N=74 Q2, N=73 Q3, N=74 Q4, N=73 P for trend  
Age, years  68 ± 10 73 ± 8 72 ± 9 72 ± 9 0.020 
Women (%) 36     (48.6%) 39     (53.4%) 41     (55.4%) 49     (67.1%) 0.027 
NYHA Class I 1      (1.4%) 1      (1.4%) 0      (0.0%) 0      (0.0%)  0.12 
NYHA Class II 61     (82.4%) 58     (79.5%) 60     (81.1%) 54     (74.0%)   
NYHA Class III 12     (16.2%) 14     (19.2%) 14     (18.9%) 19     (26.0%)   
Previous admission for heart failure 24     (32.4%) 32     (43.8%) 26     (35.1%) 40     (54.8%) 0.023 
History of atrial fibrillation 31     (41.9%) 29     (39.7%) 29     (39.2%) 33     (45.2%) 0.72 
Atrial fibrillation at screening ECG 20     (27.0%) 20     (27.4%) 20     (27.0%) 23     (31.5%) 0.58 
History of hypertension 66     (89.2%) 72     (98.6%) 66     (89.2%) 72     (98.6%) 0.13 
History of diabetes 25     (33.8%) 24     (32.9%) 29     (39.2%) 33     (45.2%) 0.11 
History of myocardial infarction 14     (18.9%) 17     (23.3%) 19     (25.7%) 9      (12.3%) 0.41 
NT-proBNP (pg/mL), median [Q1, Q3] 693.0 [368.0, 1377.0] 867.0 [499.0, 1341.0] 909.5 [512.0, 1269.5] 962.0 [628.0, 1960.5] 0.014 
Heart rate (bpm) 67.15 ± 11.76 68.03 ± 11.66 69.77 ± 12.18 72.26 ± 15.71 0.012 
Body mass index (kg/m2) 29.90 ± 5.60 29.60 ± 5.22 30.47 ± 5.87 30.00 ± 6.38 0.70 
Systolic BP (mmHg) 134.65 ± 15.06 136.29 ± 14.17 136.10 ± 13.11 133.87 ± 13.66 0.73 
Diastolic BP (mmHg) 79.31 ± 8.65 77.73 ± 9.79 77.88 ± 7.61 74.95 ± 10.93 0.008 
eGFR (mL/min per 1.73 m²) 76.18 ± 20.31 68.40 ± 15.46 65.10 ± 17.35 51.13 ± 19.61 <0.001 
ACE inhibitors or ARBs 67     (90.5%) 68     (93.2%) 73     (98.6%) 67     (91.8%) 0.47 
Beta blockers 58     (78.4%) 61     (83.6%) 59     (79.7%) 53     (72.6%) 0.33 
Aldosterone antagonists 9      (12.2%) 16     (21.9%) 19     (25.7%) 18     (24.7%) 0.05  
E' (cm/s) 7.77 ± 2.92 7.02 ± 2.48 7.43 ± 3.05 7.64 ± 2.46 0.57 
E/E' 11.41 ± 4.55 13.40 ± 6.89 12.74 ± 6.42 12.70 ± 5.69 0.17 
LA volume index (mL/m²) 35.46 ± 12.54 35.90 ± 14.93 37.08 ± 15.57 34.50 ± 11.35 0.84 
LV end diastolic volume (mL) 118.37 ± 29.41 115.44 ± 33.84 107.42 ± 26.09 107.70 ± 23.68 0.11 
LV ejection fraction (%) 56.65 ± 7.00 57.89 ± 9.71 59.62 ± 7.16 58.81 ± 6.77 0.06 
LV mass index (g/m²) 73.23 ± 17.35 81.46 ± 25.00 77.92 ± 21.16 77.39 ± 20.80 0.29 
Relative wall thickness 0.35 ± 0.05 0.37 ± 0.07 0.37 ± 0.08 0.38 ± 0.08 0.004 
Tricuspid regurgitant velocity (m/s) 2.43 ± 0.33 2.50 ± 0.36 2.60 ± 0.32 2.47 ± 0.49 0.31 
LA strain (%) 22.10 ± 9.31 19.84 ± 7.15 22.34 ± 8.68 19.83 ± 6.24 0.40 
LV global longitudinal strain (%) -14.57 ± 3.52 -14.56 ± 3.20 -15.16 ± 3.48 -14.20 ± 3.09 0.79  
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Abbreviations: 
ACE = Angiotensin converting enzyme ARB = angiotensin receptor blocker, eGFR = estimated glomerular filtration rate, NYHA = New York Heart 
Association, NT-proBNP = N-terminal pro-B-type natriuretic peptide, BP = blood pressure, continuous data are presented as mean ± standard 
deviation, categorical data are presented as frequency and % of total. E = early diastolic filling velocity, E’ = early diastolic myocardial velocity, LA 
= left atrium, LV = left ventricular.  
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Supplemental TABLE 2. Baseline Characteristics According to MMP-2 Quartiles 
 Q1  N=62 Q2 N=62 Q3 N=62 Q4 N=61 P for trend  
Age, years  68 ± 10 72 ± 9 73 ± 8 73 ± 8 0.003 
Women (%) 36     (58.1%) 32     (51.6%) 38     (61.3%) 34     (55.7%) 0.92 
NYHA Class I 0      (0.0%) 1      (1.6%) 1      (1.6%) 0      (0.0%)  0.30 
NYHA Class II 53     (85.5%) 51     (82.3%) 46     (74.2%) 49     (80.3%)   
NYHA Class III 9      (14.5%) 10     (16.1%) 15     (24.2%) 12     (19.7%)   
Previous admission for heart failure 26     (41.9%) 20     (32.3%) 24     (38.7%) 26     (42.6%) 0.76 
History of atrial fibrillation 22     (35.5%) 30     (48.4%) 29     (46.8%) 27     (44.3%) 0.38 
Atrial fibrillation at screening ECG 14     (22.6%) 22     (35.5%) 16     (25.8%) 21     (34.4%) 0.32 
History of hypertension 58     (93.5%) 58     (93.5%) 57     (91.9%) 57     (93.4%) 0.89 
History of diabetes 19     (30.6%) 21     (33.9%) 22     (35.5%) 27     (44.3%) 0.12 
History of myocardial infarction 17     (27.4%) 16     (25.8%) 10     (16.1%) 9      (14.8%) 0.04 
NT-proBNP (pg/mL), median [Q1, Q3] 573.0 [346.5, 1022.5] 766.5 [387.0, 1273.0] 973.5 [645.0, 1590.0] 1154.0 [744.0,1853.0] <0.001 
Heart rate (bpm) 69.87 ± 12.70 67.59 ± 11.40 68.53 ± 15.40 68.02 ± 11.90 0.53 
Body mass index (kg/m2) 30.34 ± 5.61 30.19 ± 5.24 31.17 ± 6.15 30.11 ± 5.50 0.92 
Systolic BP (mmHg) 135.13 ± 14.22 136.55 ± 14.61 133.15 ± 12.00 137.16 ± 15.22 0.74 
Diastolic BP (mmHg) 80.27 ± 9.17 78.62 ± 10.01 76.57 ± 8.45 74.00 ± 10.05 <0.001 
eGFR (mL/min per 1.73 m²) 71.82 ± 21.46 66.18 ± 17.27 65.97 ± 22.51 59.52 ± 16.78 0.001 
ACE inhibitors or ARBs 60     (96.8%) 56     (90.3%) 57     (91.9%) 57     (93.4%) 0.56 
Beta blockers 47     (75.8%) 50     (80.6%) 50     (80.6%) 54     (88.5%) 0.09 
Aldosterone antagonists 14     (22.6%) 11     (17.7%) 16     (25.8%) 13     (21.3%) 0.86  
E' (cm/s) 6.85 ± 2.74 7.44 ± 2.91 6.92 ± 2.59 8.45 ± 2.80 0.17 
E/E' 11.44 ± 5.18 11.72 ± 5.38 14.86 ± 6.77 12.79 ± 6.35 0.013 
LA volume index (mL/m²) 33.13 ± 13.09 35.78 ± 13.58 37.12 ± 14.13 38.03 ± 13.32 0.042 
LV end diastolic volume (mL) 114.89 ± 31.94 115.91 ± 26.66 106.07 ± 24.37 114.51 ± 31.76 0.31 
LV ejection fraction (%) 57.47 ± 8.54 57.86 ± 8.95 59.19 ± 7.48 59.87 ± 6.08 0.028 
LV mass index (g/m²) 75.58 ± 20.12 78.31 ± 21.32 75.04 ± 20.53 79.58 ± 21.49 0.98 
Relative wall thickness 0.37 ± 0.06 0.37 ± 0.07 0.37 ± 0.05 0.38 ± 0.09 0.48 
Tricuspid regurgitant velocity (m/s) 2.41 ± 0.29 2.35 ± 0.15 2.58 ± 0.45 2.64 ± 0.45 0.004 
LA strain (%) 22.57 ± 7.70 21.24 ± 8.72 20.72 ± 6.92 20.55 ± 8.61 0.22 
LV global longitudinal strain (%) -15.25 ± 3.85 -15.03 ± 2.97 -14.42 ± 3.18 -15.18 ± 3.09 0.68  
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Abbreviations: 
ACE = Angiotensin converting enzyme ARB = angiotensin receptor blocker, eGFR = estimated glomerular filtration rate, NYHA = New York Heart 
Association, NT-proBNP = N-terminal pro-B-type natriuretic peptide, BP = blood pressure, continuous data are presented as mean ± standard 
deviation, categorical data are presented as frequency and % of total. E = early diastolic filling velocity, E’ = early diastolic myocardial velocity, LA 
= left atrium, LV = left ventricular.  
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Supplemental TABLE 3. Baseline Characteristics According to PIIINP Quartiles 
 Q1 N=45 Q2 N=44 Q3 N=44 Q4 N=45 P for trend  
Age, years  70 ± 10 70 ± 11 72 ± 8 73 ± 9 0.06 
Women (%) 22     (48.9%) 25     (56.8%) 25     (55.6%) 27     (61.4%) 0.28 
NYHA Class I 0      (0.0%) 0      (0.0%) 1      (2.2%) 1      (2.3%)  0.88 
NYHA Class II 37     (82.2%) 34     (77.3%) 36     (80.0%) 34     (77.3%)  
NYHA Class III 8      (17.8%) 10     (22.7%) 8      (17.8%) 9      (20.5%)  
Previous admission for heart failure 18     (40.0%) 14     (31.8%) 20     (44.4%) 9      (20.5%) 0.15 
History of atrial fibrillation 20     (44.4%) 19     (43.2%) 23     (51.1%) 20     (45.5%) 0.74 
Atrial fibrillation at screening ECG 15     (33.3%) 13     (29.5%) 17     (37.8%) 12     (27.3%) 0.76 
History of hypertension 44     (97.8%) 40     (90.9%) 40     (88.9%) 43     (97.7%) 0.88 
History of diabetes 23     (51.1%) 10     (22.7%) 14     (31.1%) 14     (31.8%) 0.12 
History of myocardial infarction 15     (33.3%) 13     (29.5%) 7      (15.6%) 8      (18.2%) 0.142 
NT-proBNP (pg/mL), median [Q1, Q3] 511.0 [369.0, 1018.0] 796.0 [517.0, 1267.0] 1107.0 [572.0,1800.0] 967.0 [625.0, 1507.0] 0.001 
Heart rate (bpm) 67.73 ± 12.54 65.09 ± 9.77 68.11 ± 11.91 73.36 ± 15.13 0.020 
Body mass index (kg/m2) 30.40 ± 4.38 30.32 ± 5.18 29.90 ± 5.84 31.79 ± 6.67 0.32 
Systolic BP (mmHg) 135.47 ± 12.81 133.42 ± 13.05 137.43 ± 13.96 133.87 ± 11.51 0.93 
Diastolic BP (mmHg) 79.79 ± 8.76 77.58 ± 9.56 78.32 ± 10.12 76.88 ± 9.76 0.21 
eGFR (mL/min per 1.73 m²) 72.20 ± 18.41 70.14 ± 20.06 65.82 ± 18.07 63.79 ± 17.54 0.019 
ACE inhibitors or ARBs 40     (88.9%) 43     (97.7%) 43     (95.6%) 41     (93.2%) 0.50 
Beta blockers 37     (82.2%) 34     (77.3%) 40     (88.9%) 35     (79.5%) 0.89 
Aldosterone antagonists 9      (20.0%) 11     (25.0%) 12     (26.7%) 6      (13.6%) 0.54  
E' (cm/s) 7.33 ± 2.70 7.58 ± 2.73 7.57 ± 2.98 8.19 ± 2.90 0.30 
E/E' 11.74 ± 5.66 13.39 ± 7.19 13.06 ± 5.72 11.03 ± 4.85 0.56 
LA volume index (mL/m²) 32.74 ± 12.62 38.87 ± 13.36 37.76 ± 13.05 33.83 ± 16.06 0.83 
LV end diastolic volume (mL) 122.27 ± 31.17 108.15 ± 27.74 116.64 ± 31.47 108.56 ± 22.50 0.16 
LV ejection fraction (%) 57.16 ± 8.41 57.87 ± 6.81 58.82 ± 9.70 60.45 ± 7.71 0.033 
LV mass index (g/m²) 74.45 ± 23.32 75.40 ± 17.25 73.08 ± 20.08 75.05 ± 20.04 0.96 
Relative wall thickness 0.35 ± 0.08 0.35 ± 0.06 0.37 ± 0.06 0.37 ± 0.06 0.17 
Tricuspid regurgitant velocity (m/s) 2.42 ± 0.35 2.53 ± 0.36 2.51 ± 0.36 2.52 ± 0.30 0.68 
LA strain (%) 22.78 ± 7.44 18.80 ± 7.71 21.96 ± 8.89 23.31 ± 8.26 0.52 
LV global longitudinal strain (%) -15.39 ± 3.17 -14.67 ± 2.96 -15.22 ± 3.22 -15.55 ± 2.77 0.72  
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Abbreviations: 
ACE = Angiotensin converting enzyme ARB = angiotensin receptor blocker, eGFR = estimated glomerular filtration rate, NYHA = New York Heart 
Association, NT-proBNP = N-terminal pro-B-type natriuretic peptide, BP = blood pressure, continuous data are presented as mean ± standard 
deviation, categorical data are presented as frequency and % of total. E = early diastolic filling velocity, E’ = early diastolic myocardial velocity, LA 
= left atrium, LV = left ventricular.  
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Supplemental TABLE 4. Baseline Characteristics According to sST-2 Quartiles 
 Q1 N=74 Q2 N=74 Q3 N=74 Q4 N=74 P for trend  
Age, years  69 ± 10 70 ± 10 71 ± 8 74 ± 8 0.004 
Women (%) 47     (63.5%) 45     (60.8%) 38     (51.4%) 36     (48.6%) 0.036 
NYHA Class I 0      (0.0%) 1      (1.4%) 1      (1.4%) 0      (0.0%)  0.043 
NYHA Class II 66     (89.2%) 55     (74.3%) 59     (79.7%) 54     (73.0%)  
NYHA Class III 8      (10.8%) 18     (24.3%) 14     (18.9%) 20     (27.0%)  
Previous admission for heart failure 28     (37.8%) 29     (39.2%) 33     (44.6%) 34     (45.9%) 0.25 
History of atrial fibrillation 17     (23.0%) 32     (43.2%) 33     (44.6%) 39     (52.7%) <0.001 
Atrial fibrillation at screening ECG 7      (9.5%) 20     (27.0%) 22     (29.7%) 33     (44.6%) <0.001 
History of hypertension 66     (89.2%) 72     (97.3%) 73     (98.6%) 67     (90.5%) 0.66 
History of diabetes 26     (35.1%) 21     (28.4%) 34     (45.9%) 32     (43.2%) 0.10 
History of myocardial infarction 20     (27.0%) 14     (18.9%) 13     (17.6%) 14     (18.9%) 0.22 
NT-proBNP (pg/mL), median [Q1, Q3] 773.5 [355.0, 1247.5] 715.5 [393.0, 1341.0] 957.0 [601.0, 1322.0] 1014.0 [603.0,1800.0] 0.002 
Heart rate (bpm) 69.23 ± 13.28 67.59 ± 10.67 70.18 ± 14.45 70.01 ± 13.46 0.47 
Body mass index (kg/m2) 28.57 ± 5.26 30.52 ± 6.23 30.61 ± 5.38 30.24 ± 6.09 0.09 
Systolic BP (mmHg) 134.34 ± 13.40 137.82 ± 13.19 134.34 ± 13.62 134.84 ± 15.93 0.79 
Diastolic BP (mmHg) 77.78 ± 7.73 80.02 ± 10.24 77.79 ± 8.03 73.79 ± 10.60 0.004 
eGFR (mL/min per 1.73 m²) 69.12 ± 21.46 68.47 ± 19.88 62.32 ± 20.74 61.19 ± 18.14 0.005 
ACE inhibitors or ARBs 72     (97.3%) 69     (93.2%) 67     (90.5%) 68     (91.9%) 0.15 
Beta blockers 55     (74.3%) 58     (78.4%) 61     (82.4%) 59     (79.7%) 0.34 
Aldosterone antagonists 9      (12.2%) 13     (17.6%) 22     (29.7%) 18     (24.3%) 0.021  
E' (cm/s) 7.10 ± 2.69 7.43 ± 2.77 7.72 ± 2.60 7.54 ± 2.99 0.30 
E/E' 10.98 ± 3.87 12.57 ± 6.00 13.29 ± 6.85 13.70 ± 6.63 0.06 
LA volume index (mL/m²) 31.67 ± 11.70 35.10 ± 12.93 36.40 ± 13.94 39.83 ± 14.90 <0.001 
LV end diastolic volume (mL) 114.79 ± 29.12 106.59 ± 22.81 111.27 ± 29.73 120.46 ± 33.43 0.35 
LV ejection fraction (%) 57.88 ± 9.10 58.83 ± 7.20 58.46 ± 7.25 57.33 ± 7.59 0.71 
LV mass index (g/m²) 76.34 ± 18.92 77.54 ± 21.03 79.36 ± 25.66 77.16 ± 18.49 0.76 
Relative wall thickness 0.37 ± 0.07 0.36 ± 0.06 0.37 ± 0.08 0.37 ± 0.06 0.61 
Tricuspid regurgitant velocity (m/s) 2.38 ± 0.29 2.54 ± 0.31 2.52 ± 0.40 2.58 ± 0.44 0.42 
LA strain (%) 23.94 ± 8.92 20.15 ± 7.80 21.04 ± 7.53 19.78 ± 7.46 0.025 
LV global longitudinal strain (%) -14.56 ± 3.61 -14.19 ± 3.02 -15.06 ± 3.51 -14.85 ± 3.21 0.39  
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Abbreviations: 
sST-2 = soluble form of ST2(an Interleukin-1 receptor family member), ACE = Angiotensin converting enzyme ARB = angiotensin receptor blocker, 
eGFR = estimated glomerular filtration rate, NYHA = New York Heart Association, NT-proBNP = N-terminal pro-B-type natriuretic peptide, BP = 
blood pressure, continuous data are presented as mean ± standard deviation, categorical data are presented as frequency and % of total. E = early 
diastolic filling velocity, E’ = early diastolic myocardial velocity, LA = left atrium, LV = left ventricular 
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Supplemental TABLE 1. Baseline Characteristics According to GALECTIN-3 by Quartiles 
 Q1, N=74 Q2, N=73 Q3, N=74 Q4, N=73 P for trend  
Age, years  68 ± 10 73 ± 8 72 ± 9 72 ± 9 0.020 
Women (%) 36     (48.6%) 39     (53.4%) 41     (55.4%) 49     (67.1%) 0.027 
NYHA Class I 1      (1.4%) 1      (1.4%) 0      (0.0%) 0      (0.0%)  0.12 
NYHA Class II 61     (82.4%) 58     (79.5%) 60     (81.1%) 54     (74.0%)   
NYHA Class III 12     (16.2%) 14     (19.2%) 14     (18.9%) 19     (26.0%)   
Previous admission for heart failure 24     (32.4%) 32     (43.8%) 26     (35.1%) 40     (54.8%) 0.023 
History of atrial fibrillation 31     (41.9%) 29     (39.7%) 29     (39.2%) 33     (45.2%) 0.72 
Atrial fibrillation at screening ECG 20     (27.0%) 20     (27.4%) 20     (27.0%) 23     (31.5%) 0.58 
History of hypertension 66     (89.2%) 72     (98.6%) 66     (89.2%) 72     (98.6%) 0.13 
History of diabetes 25     (33.8%) 24     (32.9%) 29     (39.2%) 33     (45.2%) 0.11 
History of myocardial infarction 14     (18.9%) 17     (23.3%) 19     (25.7%) 9      (12.3%) 0.41 
NT-proBNP (pg/mL), median [Q1, Q3] 693.0 [368.0, 1377.0] 867.0 [499.0, 1341.0] 909.5 [512.0, 1269.5] 962.0 [628.0, 1960.5] 0.014 
Heart rate (bpm) 67.15 ± 11.76 68.03 ± 11.66 69.77 ± 12.18 72.26 ± 15.71 0.012 
Body mass index (kg/m2) 29.90 ± 5.60 29.60 ± 5.22 30.47 ± 5.87 30.00 ± 6.38 0.70 
Systolic BP (mmHg) 134.65 ± 15.06 136.29 ± 14.17 136.10 ± 13.11 133.87 ± 13.66 0.73 
Diastolic BP (mmHg) 79.31 ± 8.65 77.73 ± 9.79 77.88 ± 7.61 74.95 ± 10.93 0.008 
eGFR (mL/min per 1.73 m²) 76.18 ± 20.31 68.40 ± 15.46 65.10 ± 17.35 51.13 ± 19.61 <0.001 
ACE inhibitors or ARBs 67     (90.5%) 68     (93.2%) 73     (98.6%) 67     (91.8%) 0.47 
Beta blockers 58     (78.4%) 61     (83.6%) 59     (79.7%) 53     (72.6%) 0.33 
Aldosterone antagonists 9      (12.2%) 16     (21.9%) 19     (25.7%) 18     (24.7%) 0.05  
E' (cm/s) 7.77 ± 2.92 7.02 ± 2.48 7.43 ± 3.05 7.64 ± 2.46 0.57 
E/E' 11.41 ± 4.55 13.40 ± 6.89 12.74 ± 6.42 12.70 ± 5.69 0.17 
LA volume index (mL/m²) 35.46 ± 12.54 35.90 ± 14.93 37.08 ± 15.57 34.50 ± 11.35 0.84 
LV end diastolic volume (mL) 118.37 ± 29.41 115.44 ± 33.84 107.42 ± 26.09 107.70 ± 23.68 0.11 
LV ejection fraction (%) 56.65 ± 7.00 57.89 ± 9.71 59.62 ± 7.16 58.81 ± 6.77 0.06 
LV mass index (g/m²) 73.23 ± 17.35 81.46 ± 25.00 77.92 ± 21.16 77.39 ± 20.80 0.29 
Relative wall thickness 0.35 ± 0.05 0.37 ± 0.07 0.37 ± 0.08 0.38 ± 0.08 0.004 
Tricuspid regurgitant velocity (m/s) 2.43 ± 0.33 2.50 ± 0.36 2.60 ± 0.32 2.47 ± 0.49 0.31 
LA strain (%) 22.10 ± 9.31 19.84 ± 7.15 22.34 ± 8.68 19.83 ± 6.24 0.40 
LV global longitudinal strain (%) -14.57 ± 3.52 -14.56 ± 3.20 -15.16 ± 3.48 -14.20 ± 3.09 0.79  
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Abbreviations: 
ACE = Angiotensin converting enzyme ARB = angiotensin receptor blocker, eGFR = estimated glomerular filtration rate, NYHA = New York Heart 
Association, NT-proBNP = N-terminal pro-B-type natriuretic peptide, BP = blood pressure, continuous data are presented as mean ± standard 
deviation, categorical data are presented as frequency and % of total. E = early diastolic filling velocity, E’ = early diastolic myocardial velocity, LA 
= left atrium, LV = left ventricular.  
4 12/7/15 
 
 
Supplemental TABLE 2. Baseline Characteristics According to MMP-2 Quartiles 
 Q1  N=62 Q2 N=62 Q3 N=62 Q4 N=61 P for trend  
Age, years  68 ± 10 72 ± 9 73 ± 8 73 ± 8 0.003 
Women (%) 36     (58.1%) 32     (51.6%) 38     (61.3%) 34     (55.7%) 0.92 
NYHA Class I 0      (0.0%) 1      (1.6%) 1      (1.6%) 0      (0.0%)  0.30 
NYHA Class II 53     (85.5%) 51     (82.3%) 46     (74.2%) 49     (80.3%)   
NYHA Class III 9      (14.5%) 10     (16.1%) 15     (24.2%) 12     (19.7%)   
Previous admission for heart failure 26     (41.9%) 20     (32.3%) 24     (38.7%) 26     (42.6%) 0.76 
History of atrial fibrillation 22     (35.5%) 30     (48.4%) 29     (46.8%) 27     (44.3%) 0.38 
Atrial fibrillation at screening ECG 14     (22.6%) 22     (35.5%) 16     (25.8%) 21     (34.4%) 0.32 
History of hypertension 58     (93.5%) 58     (93.5%) 57     (91.9%) 57     (93.4%) 0.89 
History of diabetes 19     (30.6%) 21     (33.9%) 22     (35.5%) 27     (44.3%) 0.12 
History of myocardial infarction 17     (27.4%) 16     (25.8%) 10     (16.1%) 9      (14.8%) 0.04 
NT-proBNP (pg/mL), median [Q1, Q3] 573.0 [346.5, 1022.5] 766.5 [387.0, 1273.0] 973.5 [645.0, 1590.0] 1154.0 [744.0,1853.0] <0.001 
Heart rate (bpm) 69.87 ± 12.70 67.59 ± 11.40 68.53 ± 15.40 68.02 ± 11.90 0.53 
Body mass index (kg/m2) 30.34 ± 5.61 30.19 ± 5.24 31.17 ± 6.15 30.11 ± 5.50 0.92 
Systolic BP (mmHg) 135.13 ± 14.22 136.55 ± 14.61 133.15 ± 12.00 137.16 ± 15.22 0.74 
Diastolic BP (mmHg) 80.27 ± 9.17 78.62 ± 10.01 76.57 ± 8.45 74.00 ± 10.05 <0.001 
eGFR (mL/min per 1.73 m²) 71.82 ± 21.46 66.18 ± 17.27 65.97 ± 22.51 59.52 ± 16.78 0.001 
ACE inhibitors or ARBs 60     (96.8%) 56     (90.3%) 57     (91.9%) 57     (93.4%) 0.56 
Beta blockers 47     (75.8%) 50     (80.6%) 50     (80.6%) 54     (88.5%) 0.09 
Aldosterone antagonists 14     (22.6%) 11     (17.7%) 16     (25.8%) 13     (21.3%) 0.86  
E' (cm/s) 6.85 ± 2.74 7.44 ± 2.91 6.92 ± 2.59 8.45 ± 2.80 0.17 
E/E' 11.44 ± 5.18 11.72 ± 5.38 14.86 ± 6.77 12.79 ± 6.35 0.013 
LA volume index (mL/m²) 33.13 ± 13.09 35.78 ± 13.58 37.12 ± 14.13 38.03 ± 13.32 0.042 
LV end diastolic volume (mL) 114.89 ± 31.94 115.91 ± 26.66 106.07 ± 24.37 114.51 ± 31.76 0.31 
LV ejection fraction (%) 57.47 ± 8.54 57.86 ± 8.95 59.19 ± 7.48 59.87 ± 6.08 0.028 
LV mass index (g/m²) 75.58 ± 20.12 78.31 ± 21.32 75.04 ± 20.53 79.58 ± 21.49 0.98 
Relative wall thickness 0.37 ± 0.06 0.37 ± 0.07 0.37 ± 0.05 0.38 ± 0.09 0.48 
Tricuspid regurgitant velocity (m/s) 2.41 ± 0.29 2.35 ± 0.15 2.58 ± 0.45 2.64 ± 0.45 0.004 
LA strain (%) 22.57 ± 7.70 21.24 ± 8.72 20.72 ± 6.92 20.55 ± 8.61 0.22 
LV global longitudinal strain (%) -15.25 ± 3.85 -15.03 ± 2.97 -14.42 ± 3.18 -15.18 ± 3.09 0.68  
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Abbreviations: 
ACE = Angiotensin converting enzyme ARB = angiotensin receptor blocker, eGFR = estimated glomerular filtration rate, NYHA = New York Heart 
Association, NT-proBNP = N-terminal pro-B-type natriuretic peptide, BP = blood pressure, continuous data are presented as mean ± standard 
deviation, categorical data are presented as frequency and % of total. E = early diastolic filling velocity, E’ = early diastolic myocardial velocity, LA 
= left atrium, LV = left ventricular.  
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Supplemental TABLE 3. Baseline Characteristics According to PIIINP Quartiles 
 Q1 N=45 Q2 N=44 Q3 N=44 Q4 N=45 P for trend  
Age, years  70 ± 10 70 ± 11 72 ± 8 73 ± 9 0.06 
Women (%) 22     (48.9%) 25     (56.8%) 25     (55.6%) 27     (61.4%) 0.28 
NYHA Class I 0      (0.0%) 0      (0.0%) 1      (2.2%) 1      (2.3%)  0.88 
NYHA Class II 37     (82.2%) 34     (77.3%) 36     (80.0%) 34     (77.3%)  
NYHA Class III 8      (17.8%) 10     (22.7%) 8      (17.8%) 9      (20.5%)  
Previous admission for heart failure 18     (40.0%) 14     (31.8%) 20     (44.4%) 9      (20.5%) 0.15 
History of atrial fibrillation 20     (44.4%) 19     (43.2%) 23     (51.1%) 20     (45.5%) 0.74 
Atrial fibrillation at screening ECG 15     (33.3%) 13     (29.5%) 17     (37.8%) 12     (27.3%) 0.76 
History of hypertension 44     (97.8%) 40     (90.9%) 40     (88.9%) 43     (97.7%) 0.88 
History of diabetes 23     (51.1%) 10     (22.7%) 14     (31.1%) 14     (31.8%) 0.12 
History of myocardial infarction 15     (33.3%) 13     (29.5%) 7      (15.6%) 8      (18.2%) 0.142 
NT-proBNP (pg/mL), median [Q1, Q3] 511.0 [369.0, 1018.0] 796.0 [517.0, 1267.0] 1107.0 [572.0,1800.0] 967.0 [625.0, 1507.0] 0.001 
Heart rate (bpm) 67.73 ± 12.54 65.09 ± 9.77 68.11 ± 11.91 73.36 ± 15.13 0.020 
Body mass index (kg/m2) 30.40 ± 4.38 30.32 ± 5.18 29.90 ± 5.84 31.79 ± 6.67 0.32 
Systolic BP (mmHg) 135.47 ± 12.81 133.42 ± 13.05 137.43 ± 13.96 133.87 ± 11.51 0.93 
Diastolic BP (mmHg) 79.79 ± 8.76 77.58 ± 9.56 78.32 ± 10.12 76.88 ± 9.76 0.21 
eGFR (mL/min per 1.73 m²) 72.20 ± 18.41 70.14 ± 20.06 65.82 ± 18.07 63.79 ± 17.54 0.019 
ACE inhibitors or ARBs 40     (88.9%) 43     (97.7%) 43     (95.6%) 41     (93.2%) 0.50 
Beta blockers 37     (82.2%) 34     (77.3%) 40     (88.9%) 35     (79.5%) 0.89 
Aldosterone antagonists 9      (20.0%) 11     (25.0%) 12     (26.7%) 6      (13.6%) 0.54  
E' (cm/s) 7.33 ± 2.70 7.58 ± 2.73 7.57 ± 2.98 8.19 ± 2.90 0.30 
E/E' 11.74 ± 5.66 13.39 ± 7.19 13.06 ± 5.72 11.03 ± 4.85 0.56 
LA volume index (mL/m²) 32.74 ± 12.62 38.87 ± 13.36 37.76 ± 13.05 33.83 ± 16.06 0.83 
LV end diastolic volume (mL) 122.27 ± 31.17 108.15 ± 27.74 116.64 ± 31.47 108.56 ± 22.50 0.16 
LV ejection fraction (%) 57.16 ± 8.41 57.87 ± 6.81 58.82 ± 9.70 60.45 ± 7.71 0.033 
LV mass index (g/m²) 74.45 ± 23.32 75.40 ± 17.25 73.08 ± 20.08 75.05 ± 20.04 0.96 
Relative wall thickness 0.35 ± 0.08 0.35 ± 0.06 0.37 ± 0.06 0.37 ± 0.06 0.17 
Tricuspid regurgitant velocity (m/s) 2.42 ± 0.35 2.53 ± 0.36 2.51 ± 0.36 2.52 ± 0.30 0.68 
LA strain (%) 22.78 ± 7.44 18.80 ± 7.71 21.96 ± 8.89 23.31 ± 8.26 0.52 
LV global longitudinal strain (%) -15.39 ± 3.17 -14.67 ± 2.96 -15.22 ± 3.22 -15.55 ± 2.77 0.72  
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Abbreviations: 
ACE = Angiotensin converting enzyme ARB = angiotensin receptor blocker, eGFR = estimated glomerular filtration rate, NYHA = New York Heart 
Association, NT-proBNP = N-terminal pro-B-type natriuretic peptide, BP = blood pressure, continuous data are presented as mean ± standard 
deviation, categorical data are presented as frequency and % of total. E = early diastolic filling velocity, E’ = early diastolic myocardial velocity, LA 
= left atrium, LV = left ventricular.  
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Supplemental TABLE 4. Baseline Characteristics According to sST-2 Quartiles 
 Q1 N=74 Q2 N=74 Q3 N=74 Q4 N=74 P for trend  
Age, years  69 ± 10 70 ± 10 71 ± 8 74 ± 8 0.004 
Women (%) 47     (63.5%) 45     (60.8%) 38     (51.4%) 36     (48.6%) 0.036 
NYHA Class I 0      (0.0%) 1      (1.4%) 1      (1.4%) 0      (0.0%)  0.043 
NYHA Class II 66     (89.2%) 55     (74.3%) 59     (79.7%) 54     (73.0%)  
NYHA Class III 8      (10.8%) 18     (24.3%) 14     (18.9%) 20     (27.0%)  
Previous admission for heart failure 28     (37.8%) 29     (39.2%) 33     (44.6%) 34     (45.9%) 0.25 
History of atrial fibrillation 17     (23.0%) 32     (43.2%) 33     (44.6%) 39     (52.7%) <0.001 
Atrial fibrillation at screening ECG 7      (9.5%) 20     (27.0%) 22     (29.7%) 33     (44.6%) <0.001 
History of hypertension 66     (89.2%) 72     (97.3%) 73     (98.6%) 67     (90.5%) 0.66 
History of diabetes 26     (35.1%) 21     (28.4%) 34     (45.9%) 32     (43.2%) 0.10 
History of myocardial infarction 20     (27.0%) 14     (18.9%) 13     (17.6%) 14     (18.9%) 0.22 
NT-proBNP (pg/mL), median [Q1, Q3] 773.5 [355.0, 1247.5] 715.5 [393.0, 1341.0] 957.0 [601.0, 1322.0] 1014.0 [603.0,1800.0] 0.002 
Heart rate (bpm) 69.23 ± 13.28 67.59 ± 10.67 70.18 ± 14.45 70.01 ± 13.46 0.47 
Body mass index (kg/m2) 28.57 ± 5.26 30.52 ± 6.23 30.61 ± 5.38 30.24 ± 6.09 0.09 
Systolic BP (mmHg) 134.34 ± 13.40 137.82 ± 13.19 134.34 ± 13.62 134.84 ± 15.93 0.79 
Diastolic BP (mmHg) 77.78 ± 7.73 80.02 ± 10.24 77.79 ± 8.03 73.79 ± 10.60 0.004 
eGFR (mL/min per 1.73 m²) 69.12 ± 21.46 68.47 ± 19.88 62.32 ± 20.74 61.19 ± 18.14 0.005 
ACE inhibitors or ARBs 72     (97.3%) 69     (93.2%) 67     (90.5%) 68     (91.9%) 0.15 
Beta blockers 55     (74.3%) 58     (78.4%) 61     (82.4%) 59     (79.7%) 0.34 
Aldosterone antagonists 9      (12.2%) 13     (17.6%) 22     (29.7%) 18     (24.3%) 0.021  
E' (cm/s) 7.10 ± 2.69 7.43 ± 2.77 7.72 ± 2.60 7.54 ± 2.99 0.30 
E/E' 10.98 ± 3.87 12.57 ± 6.00 13.29 ± 6.85 13.70 ± 6.63 0.06 
LA volume index (mL/m²) 31.67 ± 11.70 35.10 ± 12.93 36.40 ± 13.94 39.83 ± 14.90 <0.001 
LV end diastolic volume (mL) 114.79 ± 29.12 106.59 ± 22.81 111.27 ± 29.73 120.46 ± 33.43 0.35 
LV ejection fraction (%) 57.88 ± 9.10 58.83 ± 7.20 58.46 ± 7.25 57.33 ± 7.59 0.71 
LV mass index (g/m²) 76.34 ± 18.92 77.54 ± 21.03 79.36 ± 25.66 77.16 ± 18.49 0.76 
Relative wall thickness 0.37 ± 0.07 0.36 ± 0.06 0.37 ± 0.08 0.37 ± 0.06 0.61 
Tricuspid regurgitant velocity (m/s) 2.38 ± 0.29 2.54 ± 0.31 2.52 ± 0.40 2.58 ± 0.44 0.42 
LA strain (%) 23.94 ± 8.92 20.15 ± 7.80 21.04 ± 7.53 19.78 ± 7.46 0.025 
LV global longitudinal strain (%) -14.56 ± 3.61 -14.19 ± 3.02 -15.06 ± 3.51 -14.85 ± 3.21 0.39  
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Abbreviations: 
sST-2 = soluble form of ST2(an Interleukin-1 receptor family member), ACE = Angiotensin converting enzyme ARB = angiotensin receptor blocker, 
eGFR = estimated glomerular filtration rate, NYHA = New York Heart Association, NT-proBNP = N-terminal pro-B-type natriuretic peptide, BP = 
blood pressure, continuous data are presented as mean ± standard deviation, categorical data are presented as frequency and % of total. E = early 
diastolic filling velocity, E’ = early diastolic myocardial velocity, LA = left atrium, LV = left ventricular 
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